FDA announces labeling changes to opioid pain medications
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain the risks associated with long-term use. The updates include presenting clearer risk information, stronger dosing warnings, clarified language on use limits, treatment guidance and more. Manufacturers were given 30 days to submit their labeling updates to the FDA for review.
Related News Articles
Headline
The cigarette smoking rate among U.S. adults dropped to 9.9% in 2024, the lowest level ever recorded, according to a report by the New England Journal of…
Headline
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol…
Headline
The Substance Abuse and Mental Health Services Administration announced March 6 that it will award $69.1 million in grants for mental health and suicide…
Headline
The Food and Drug Administration March 5 issued a request for information seeking public comments on potential new standards for in-home opioid disposal…
Headline
The Department of Health and Human Services Office for Civil Rights Feb. 13 announced the launch of a program to implement and enforce statutory and regulatory…
Headline
The White House issued an executive order Jan. 29 to address substance use and addiction. The order establishes the White House Great American Recovery…